Initial clinical studies using the radiotracer 68Gallium Prostate-Specific Membrane Antigen (68Ga PSMA) have shown excellent results results initiating its implementation in the work-up of prostate cancer patients [5, 43–46]. Here, FOLH1 is linked to prostate carcinoma.